Bi-Layer HIV Tablet Formulation for Stable Drug Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies for HIV require multiple medications, leading to challenges in adherence and potential drug interactions, with a need for a simplified, safe, and efficacious two-drug regimen that maintains pharmacokinetic profiles.
Innovation Solution
A bi-layer tablet formulation comprising lamivudine and dolutegravir sodium, with distinct layers optimized for favorable dissolution and pharmacokinetic properties, replicating the AUC and Cmax parameters of approved single-agent tablets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple anti-HIV medications are administered in combination, then treatment efficacy is improved, but treatment complexity and adherence difficulty increase
Solution Approach 1:
The patent combines two anti-HIV medications (dolutegravir and lamivudine) into a single bi-layer tablet formulation. This merging approach maintains the therapeutic efficacy of both drugs while simplifying the treatment regimen from multiple separate medications to one unified dosage form, directly addressing the contradiction between treatment efficacy and treatment complexity
Solution Approach 2:
The tablet is divided into two distinct layers, with each layer containing one of the active ingredients (dolutegravir in one layer, lamivudine in the other). This segmentation allows each drug to maintain its individual dissolution characteristics and pharmacokinetic profile while being delivered through a single combined formulation, resolving the contradiction by preserving drug-specific properties within a simplified regimen
2Ease of operation
If a single dosage form combining multiple drugs is created, then adherence is improved, but dissolution characteristics and pharmacokinetic profiles may be compromised
Solution Approach 1:
The bi-layer tablet structure physically separates the two drugs into distinct layers, each optimized for its specific dissolution requirements. This segmentation ensures that the dissolution characteristics of each drug remain comparable to their individual formulations, preventing compromise of pharmacokinetic profiles while achieving the adherence benefit of a single dosage form
Solution Approach 2:
Each layer of the tablet is formulated with excipients and processing conditions specifically tailored to the dissolution properties of its active ingredient. This local quality approach ensures that each drug layer maintains its optimal dissolution characteristics despite being part of a combined formulation, resolving the contradiction between ease of administration and manufacturing precision
3Object-generated harmful factors
If a two-drug regimen is used instead of three-drug regimen, then drug burden and toxicities are reduced, but antiviral activity may be insufficient
Solution Approach 1:
The patent combines dolutegravir (an integrase inhibitor) and lamivudine (a nucleoside reverse transcriptase inhibitor) into a single formulation, creating a two-drug regimen that reduces drug burden and potential toxicities compared to three-drug regimens. The synergistic antiviral activity of these two mechanistically distinct drugs maintains efficacy while simplifying treatment and reducing harmful effects
Data Source
Figure 1
Figure 2
AI summary
A novel bi-layer tablet formulation comprising HIV integrase strand transfer inhibitor dolutegravir, with the nucleoside reverse transcriptase inhibitor lamivudine.